Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma

BACKGROUND: RECORD-3 assessed non-inferiority of progression-free survival (PFS) with everolimus vs sunitinib in previously untreated patients with metastatic renal cell carcinoma. Baseline plasma sample collection and randomised design enabled correlation of circulating biomarkers with efficacy. ME...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Br J Cancer
Autori principali: Voss, Martin H, Chen, David, Marker, Mahtab, Hakimi, A Ari, Lee, Chung-Han, Hsieh, James J, Knox, Jennifer J, Voi, Maurizio, Motzer, Robert J
Natura: Artigo
Lingua:Inglês
Pubblicazione: Nature Publishing Group 2016
Soggetti:
Translational Therapeutics
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4800293/
https://ncbi.nlm.nih.gov/pubmed/26908330
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2016.21
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi